News
Deficit dihydropyrimidine dehydrogenase and its association with 5-fluorouracil toxicity
Deficit dihydropyrimidine dehydrogenase (DPD) is a risk factor for severe toxicity of 5-fluorouracil (5-FU). Below, we summarize current knowledge regarding the identification of patients with pathogenic variants of the DPYD gene and study results concerning the safety of therapy with respect to dose individualization based on genotyping.
Compression therapy in combination with surgical intervention in the treatment of venous leg ulcers and prevention of their recurrence
Compression therapy represents an important part of the treatment of venous leg ulcers; it also…
Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for…
Osteonecrosis of the Jaw Associated with Antiresorptive Pharmacotherapy in Oncological Patients
Antiresorptive pharmacotherapy in the form of bisphosphonates and denosumab is associated,…
Prediction of Hypocalcemia Risk in Patients Treated with Denosumab and Active Form of Vitamin D
According to new work by Japanese authors, it appears that the risk factors for the development of…
Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy
Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more…
How Does Cenobamate Compare with Third-Generation Anti-Seizure Medications in Terms of Cost-Effectiveness?
The main goal of epilepsy treatment is to achieve seizure freedom without unacceptable side effects…
Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy
The authors of a newly published study sought to answer whether the risk of developing interstitial…
Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
The work cited below presents freshly updated results from the Quazar AML-001 study evaluating…
Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease
Intensive chemotherapy for patients newly diagnosed with acute myeloid leukemia (AML) often…